Most seasonal flu vaccines are designed to coach the immune system to defend towards three or 4 totally different frequent strains of flu, however a “common” influenza vaccine would possibly sometime present safety towards many extra.
The vaccine candidate below investigation, FluMos-v2, was designed by researchers at NIAID’s Vaccine Analysis Heart (VRC). It’s an adaptation of an earlier common flu vaccine candidate, FluMos-v1, which started first-in-human testing in 2021 and remains to be present process trials.
Security and Efficacy of Flu Vaccines in Animal Trials
FluMos-v2 is designed to induce antibodies towards many alternative influenza virus strains by displaying a part of the influenza virus hemagglutinin (HA) protein in repeating patterns on self-assembling nanoparticle scaffolds. Publicity to those innocent fragments of virus proteins prepares the immune system to acknowledge and struggle the precise virus. When examined in animals, the experimental vaccine resulted in strong antibody responses.
Whereas the FluMos-v1 vaccine candidate shows HA from 4 strains of influenza virus, FluMos-v2 shows HA from six: 4 influenza A viruses and two influenza B viruses. The researchers anticipate that this can additional broaden vaccine recipients’ immunity, offering safety towards a greater variety of influenza viruses.
The brand new scientific trial is predicted to enroll 24 wholesome volunteers, aged 18-50 years, who will obtain two intramuscular injections of the FluMos-v2 vaccine candidate. These injections shall be given 16 weeks aside.
At first, individuals shall be enrolled within the decrease dose group (60 mcg per vaccination). If no security issues are recognized after no less than three individuals have acquired this dose, enrollment will start within the larger dose (180 mcg per vaccination) group. The examine workforce plans to enroll 12 individuals in every dosage group.
For 40 weeks after their first vaccination, individuals will obtain common follow-up telephone calls and examinations to trace their responses to the experimental vaccine. Blood samples shall be taken throughout examine visits to measure any immune responses to the vaccine candidate.
- Trial to Consider the Security, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Wholesome Adults – (https://www.clinicaltrials.gov/examine/NCT05968989)